Thompson Siegel & Walmsley’s CONMED CNMD Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-300	Closed	-$45K	–	575
2022 Q1	$45K	Hold	300	–	–	﹤0.01%	466
2021 Q4	$43K	Hold	300	–	–	﹤0.01%	483
2021 Q3	$39K	Hold	300	–	–	﹤0.01%	501
2021 Q2	$41K	Hold	300	–	–	﹤0.01%	517
2021 Q1	$39K	Hold	300	–	–	﹤0.01%	494
2020 Q4	$34K	Hold	300	–	–	﹤0.01%	482
2020 Q3	$24K	Hold	300	–	–	﹤0.01%	488
2020 Q2	$22K	Buy	+300	New	+$20.9K	﹤0.01%	494

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thompson Siegel & Walmsley's CNMD Position: Q2 2022 in Review

Thompson Siegel & Walmsley sold out of CONMED (CNMD) in Q2 2022, closing a stake of 300 shares — an estimated $45K sold.

Thompson Siegel & Walmsley first reported a position in CNMD in Q2 2020 and held it in 8 quarters. The position peaked at $45K in Q1 2022. 280 funds tracked by Wall St. Rank hold CNMD as of Q2 2022.

Thompson Siegel & Walmsley reported no remaining CONMED position as of Q2 2022 after selling out during the quarter.
Thompson Siegel & Walmsley sold 300 CONMED shares in Q2 2022, an estimated $45K.
Thompson Siegel & Walmsley first reported a position in CONMED in Q2 2020 and held it in 8 quarters.
Thompson Siegel & Walmsley's CONMED position peaked at $45K in Q1 2022.
280 funds tracked by Wall St. Rank held CONMED as of Q2 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2022, filed 22 Jul 2022.